Ossium Health announced today that Kevin Caldwell, CEO, Co-Founder & President, will present at the annual Cell & Gene Meeting on the Mesa to be held October 10-12 in Carlsbad, California and live streamed globally.

Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is a three-day conference featuring more than 120 dedicated company presentations by leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies, as well as over 100 panelists and featured speakers.

Kevin will provide attendees with a first glimpse inside Ossium’s landmark clinical study recently launched in collaboration with the National Marrow Donor Program® (NMDP) / Be The Match®. This study’s initiation serves as a major milestone for the blood cancer community as it will provide safety and efficacy data on Ossium’s bone marrow and unlock a new source of on-demand bone marrow for patients. In addition, Kevin will provide an update on Ossium’s phase 1 study of allogeneic bone marrow-derived cell therapy for the treatment of steroid-refractory acute graft versus host disease and Ossium’s upcoming launch of OssiGraft™, a next-generation viable bone allograft.

The following are specific details regarding Ossium Health’s presentation at the conference:

Event: 2023 Cell & Gene Meeting on the Mesa

Date: Wednesday, October 11, 2023

Time: 5:15 - 5:30 pm Pacific Time

Location: Ecolab Life Sciences Ballroom

Park Hyatt Aviara Resort, 7100 Aviara Resort Dr., Carlsbad, CA 92011

Virtual attendance is available which includes a livestream of Ossium Health’s presentation and the ability to view all conference sessions on-demand. Please visit https://meetingonthemesa.com for full information including registration.

Complimentary attendance at this event is available for credentialed investors and members of the media only. Investors should contact Savannah Bryant at sbryant@alliancerm.org and interested media should contact Stephen Majors at smajors@alliancerm.org.

About Ossium Health

Ossium Health is a bioengineering company that leverages its proprietary organ donor bone marrow banking platform to develop stem cell therapies for patients with life-threatening blood and immune diseases. Founded in 2016, the company is led by Kevin Caldwell, its CEO, Co-Founder & President, and by Erik Woods, its Chief Science Officer, Co-Founder & EVP. Ossium Health’s manufacturing and testing facilities are registered with the FDA, accredited by the Commission on Office Laboratory Accreditation (COLA), and certified under the Clinical Laboratory Improvement Amendment (CLIA).

View source version on businesswire.com: https://www.businesswire.com/news/home/20231009661075/en/